FDA approved Thermo Fisher Scientific's Oncomine Dx Express Test for lung cancer mutations.

Thermo Fisher Scientific Inc. (NYSE:TMO) received FDA approval for its Oncomine Dx Express Test on the Ion Torrent Genexus Dx Integrated Sequencer, authorized for in vitro diagnostic and companion diagnostic for Dizal’s ZEGFROVY for non-small cell lung cancer patients. The test also detects mutations across 46 genes in solid tumors. This advancement brings rapid next-generation sequencing closer to patients, delivering results in 24 hours, crucial for timely cancer care. Thermo Fisher Scientific Inc. (NYSE:TMO) focuses on accelerating research, improving patient health, and boosting laboratory efficiency.

Read more at Yahoo Finance: FDA Approved Thermo Fisher Scientific’s (TMO) Oncomine Dx Express Test